AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2882767 — intervention group
Group type: EXPERIMENTAL
Intervention: elixir preparation of temazepam
Number of subjects: 0
Study 2882767 — intervention group
Group type: EXPERIMENTAL
Intervention: capsule preparation of temazepam
Number of subjects: 0
Study 2882767 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. temazepam
Number of subjects: 0
Study 28972803 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual diameter measurements
Number of subjects: 93
Study 28972803 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-automatic volume measurements
Number of subjects: 93
Study 26399958 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electroacupuncture (TEA)
Number of subjects: 13
Study 26399958 — intervention group
Group type: COMPARATOR
Intervention: Sham-TEA
Number of subjects: 13
Study 26399958 — intervention group
Group type: COMPARATOR
Intervention: Cold nutrient liquid
Number of subjects: 13
Study 23929260 — intervention group
Group type: EXPERIMENTAL
Intervention: H-AGE meal (roasted)
Number of subjects: 19
Study 23929260 — intervention group
Group type: COMPARATOR
Intervention: L-AGE meal (steamed)
Number of subjects: 19
Study 22730632 — intervention group
Group type: EXPERIMENTAL
Intervention: Active distraction (EMLA plus videogame)
Number of subjects: 109
Study 22730632 — intervention group
Group type: COMPARATOR
Intervention: Conventional care (EMLA only)
Number of subjects: 109
Study 20483522 — intervention group
Group type: EXPERIMENTAL
Intervention: Auscultation of heart rate at birth
Number of subjects: 61
Study 20483522 — intervention group
Group type: EXPERIMENTAL
Intervention: Auscultation of heart rate during ventilation
Number of subjects: 61
Study 20483522 — intervention group
Group type: EXPERIMENTAL
Intervention: Auscultation of heart rate after compressions and ventilation
Number of subjects: 61
Study 20483522 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall heart rate assessments
Number of subjects: 61
Study 18334867 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behaviour therapy (CBT) in addition to mebeverine
Number of subjects: 0
Study 18334867 — intervention group
Group type: COMPARATOR
Intervention: Mebeverine alone
Number of subjects: 0
Study 15616772 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG + FAM (immunochemotherapy)
Number of subjects: 156
Study 15616772 — intervention group
Group type: EXPERIMENTAL
Intervention: FAM (chemotherapy)
Number of subjects: 156
Study 15616772 — intervention group
Group type: COMPARATOR
Intervention: Control (surgery only)
Number of subjects: 156
Study 11335732 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced osmolarity ORS solution
Number of subjects: 675
Study 9267272 — intervention group
Group type: EXPERIMENTAL
Intervention: Preemptive analgesia with a combination of lidocaine hydrochloride and bupivacaine hydrochloride
Number of subjects: 0
Study 9267272 — intervention group
Group type: COMPARATOR
Intervention: Preemptive analgesia with saline solution
Number of subjects: 0
Study 9267272 — intervention group
Group type: COMPARATOR
Intervention: Nothing
Number of subjects: 0
Study 8387084 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinic systolic blood pressure
Number of subjects: 97
Study 8387084 — intervention group
Group type: COMPARATOR
Intervention: Daytime ambulatory blood pressure
Number of subjects: 97
Study 8387084 — intervention group
Group type: EXPERIMENTAL
Intervention: Sum of SV1 + RV5 (ECG voltages)
Number of subjects: 97
Study 8387084 — intervention group
Group type: EXPERIMENTAL
Intervention: Residual ambulatory blood pressure levels
Number of subjects: 97
Study 3554125 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin-clavulanate potassium
Number of subjects: 133
Study 3554125 — intervention group
Group type: COMPARATOR
Intervention: Cefaclor
Number of subjects: 133
Study 30446405 — intervention group
Group type: EXPERIMENTAL
Intervention: ProTaper Next (PTN, Dentsply Sirona)
Number of subjects: 135
Study 30446405 — intervention group
Group type: EXPERIMENTAL
Intervention: One Shape (OS, Micro‐Mega)
Number of subjects: 135
Study 30446405 — intervention group
Group type: EXPERIMENTAL
Intervention: One G (OG) files (Micro‐Mega, Besançon, France)
Number of subjects: 135
Study 30446405 — intervention group
Group type: EXPERIMENTAL
Intervention: ProGlider (PG) files (Dentsply Sirona) with WaveOne Gold (WOG, Dentsply Sirona)
Number of subjects: 135
Study 30446405 — intervention group
Group type: COMPARATOR
Intervention: K/OS and K/PTN
Number of subjects: 135
Study 30446405 — intervention group
Group type: COMPARATOR
Intervention: K/PTN, K/OS, and OG/OS
Number of subjects: 135
Study 30446405 — intervention group
Group type: COMPARATOR
Intervention: K/PTN and K/OS
Number of subjects: 135
Study 29678195 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensorimotor therapy
Number of subjects: 60
Study 29678195 — intervention group
Group type: COMPARATOR
Intervention: Attention‐matched motor therapy
Number of subjects: 60
Study 27118620 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal denervation
Number of subjects: 364
Study 27118620 — intervention group
Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 364
Study 24572702 — intervention group
Group type: EXPERIMENTAL
Intervention: Watermelon supplementation
Number of subjects: 13
Study 24572702 — intervention group
Group type: COMPARATOR
Intervention: Placebo supplementation
Number of subjects: 13
Study 22237688 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine (G+MET)
Number of subjects: 110
Study 22237688 — intervention group
Group type: EXPERIMENTAL
Intervention: NPH insulin (NPH+MET)
Number of subjects: 110
Study 19417734 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-dose tirofiban (0.4 microg x kg(‐1) x min(‐1) bolus for 30 min, followed by 0.10 microg x kg(‐1) x min(‐1) infusion for 36-48 h)
Number of subjects: 94
Study 19417734 — intervention group
Group type: COMPARATOR
Intervention: Low-dose tirofiban (0.4 microg x kg(‐1) x min(‐1) bolus for 30 min, followed by 0.075 microg x kg(‐1) x min(‐1) infusion for 36-48 h)
Number of subjects: 94
Study 19417734 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-dose tirofiban
Number of subjects: 94
Study 19417734 — intervention group
Group type: COMPARATOR
Intervention: Low-dose tirofiban
Number of subjects: 94
Study 17448840 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative Symptom Severity (PoSSe) scale
Number of subjects: 255
Study 17448840 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized surgical and analgesic protocols
Number of subjects: 255
Study 17448840 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical assessment of trismus and pain
Number of subjects: 255
Study 15185887 — intervention group
Group type: COMPARATOR
Intervention: Stented xenografts (Group 1)
Number of subjects: 668
Study 15185887 — intervention group
Group type: EXPERIMENTAL
Intervention: Stentless xenografts (Group 2)
Number of subjects: 668
Study 11061578 — intervention group
Group type: EXPERIMENTAL
Intervention: Grapefruit juice (200 mL double-strength three times a day for 3 days)
Number of subjects: 10
Study 11061578 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 24 hours after grapefruit juice
Number of subjects: 10
Study 11061578 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 3 days after grapefruit juice
Number of subjects: 10
Study 11061578 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 7 days after grapefruit juice
Number of subjects: 10
Study 11061578 — intervention group
Group type: EXPERIMENTAL
Intervention: Grapefruit juice with simvastatin
Number of subjects: 10
Study 11061578 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 3 or 7 days after grapefruit juice
Number of subjects: 10
Study 9311179 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal misoprostol (100 microgram tablets)
Number of subjects: 110
Study 9311179 — intervention group
Group type: COMPARATOR
Intervention: Intracervical prostaglandin E2 gel (1.5 mg)
Number of subjects: 110
Study 9311179 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal misoprostol
Number of subjects: 110
Study 9311179 — intervention group
Group type: COMPARATOR
Intervention: Intracervical prostaglandin E2 gel
Number of subjects: 110
Study 8393389 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril therapy
Number of subjects: 14
Study 8393389 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 8393389 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril therapy in subjects with high norepinephrine levels
Number of subjects: 14
Study 8393389 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril therapy in subjects with low norepinephrine levels
Number of subjects: 14
Study 2878272 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecally administered natural human fibroblast interferon (IFN-B)
Number of subjects: 69
Study 2878272 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 29346838 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS-962212 (20 mg h-1)
Number of subjects: 20
Study 29346838 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 28684128 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual plus household MRSA decolonization
Number of subjects: 77
Study 28684128 — intervention group
Group type: COMPARATOR
Intervention: Individual MRSA decolonization
Number of subjects: 77
Study 25028958 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein low-fat (HPLF) diet
Number of subjects: 13
Study 25028958 — intervention group
Group type: COMPARATOR
Intervention: Moderate-protein moderate-fat (MPMF) diet
Number of subjects: 13
Study 23231446 — intervention group
Group type: EXPERIMENTAL
Intervention: Acamprosate
Number of subjects: 426
Study 23231446 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 426
Study 23231446 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 426
Study 21511818 — intervention group
Group type: EXPERIMENTAL
Intervention: HealthWise intervention
Number of subjects: 4040
Study 21511818 — intervention group
Group type: COMPARATOR
Intervention: Comparison group
Number of subjects: 4040
Study 18303467 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised Swiss ball exercise
Number of subjects: 60
Study 18303467 — intervention group
Group type: COMPARATOR
Intervention: Exercise advice group
Number of subjects: 60
Study 18303467 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Supervised exercise and Exercise advice)
Number of subjects: 60
Study 18303467 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report measures
Number of subjects: 60
Study 18303467 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term follow-up
Number of subjects: 60
Study 17238380 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized Decision Support System (CDSS)
Number of subjects: 90162
Study 17238380 — intervention group
Group type: COMPARATOR
Intervention: No CDSS (Control)
Number of subjects: 90162
Study 14996065 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical tacrolimus 0.1% ointment under occlusion for 48 h
Number of subjects: 28
Study 14996065 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate 0.1% ointment under occlusion for 48 h
Number of subjects: 28
Study 14996065 — intervention group
Group type: COMPARATOR
Intervention: Petrolatum
Number of subjects: 28
Study 10626714 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2%/2 microg x ml(‐1) fentanyl
Number of subjects: 32
Study 10626714 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 0.125%/2 microg x ml(‐1) fentanyl
Number of subjects: 32
Study 9127122 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticlopidine (250 mg/day)
Number of subjects: 1632
Study 9127122 — intervention group
Group type: COMPARATOR
Intervention: Indobufen (200 mg/day)
Number of subjects: 1632
Study 8233639 — intervention group
Group type: EXPERIMENTAL
Intervention: Pefloxacin (400 mg q 12 h)
Number of subjects: 10
Study 8233639 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin (200 mg q 12 h)
Number of subjects: 10
Study 8233639 — intervention group
Group type: EXPERIMENTAL
Intervention: Pefloxacin and Ofloxacin with Ketoprofen (100 mg daily)
Number of subjects: 10
Study 31823745 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based sustainability intervention delivered to intervention clubs over three consecutive Australian winter sports seasons (April-September 2015-2017).
Number of subjects: 668
Study 31823745 — intervention group
Group type: COMPARATOR
Intervention: Usual support from the national Good Sports Program (control group).
Number of subjects: 668
Study 28947569 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood pressure control
Number of subjects: 2
Study 28947569 — intervention group
Group type: COMPARATOR
Intervention: Standard blood pressure control
Number of subjects: 2
Study 27044069 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants who endorsed false beliefs about biological differences rated the black patient's pain as lower and made less accurate treatment recommendations.
Number of subjects: 0
Study 27044069 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants who did not endorse false beliefs about biological differences rated the black patient's pain as higher.
Number of subjects: 0
Study 25558905 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-vitamin-mineral preparation supplemented with 300 mg guarana (Ac)
Number of subjects: 56
Study 25558905 — intervention group
Group type: COMPARATOR
Intervention: Caffeine supplement (C)
Number of subjects: 56
Study 25558905 — intervention group
Group type: COMPARATOR
Intervention: Placebo supplement (Pl)
Number of subjects: 56
Study 22014645 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin plus cilostazol
Number of subjects: 76
Study 22014645 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 76
Study 19560638 — intervention group
Group type: EXPERIMENTAL
Intervention: BPTB autografts
Number of subjects: 18
Study 19560638 — intervention group
Group type: EXPERIMENTAL
Intervention: ST/G autografts
Number of subjects: 18
Study 19560638 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 18
Study 18575221 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapalene 0.1% gel for 12 weeks
Number of subjects: 201
Study 18575221 — intervention group
Group type: COMPARATOR
Intervention: Adapalene 0.1% gel for 6 weeks followed by tazarotene 0.1% cream for 6 weeks (switch therapy)
Number of subjects: 201
Study 16009690 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg twice daily
Number of subjects: 36
Study 16009690 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 12477620 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE-I (5 mg of enalapril)
Number of subjects: 35
Study 12477620 — intervention group
Group type: COMPARATOR
Intervention: MVI (multivitamin placebo)
Number of subjects: 35
Study 10051800 — intervention group
Group type: EXPERIMENTAL
Intervention: Cochrane Reviews
Number of subjects: 0
Study 10051800 — intervention group
Group type: EXPERIMENTAL
Intervention: Cochrane Handbook
Number of subjects: 0
Study 10051800 — intervention group
Group type: EXPERIMENTAL
Intervention: Software program for Cochrane Reviews
Number of subjects: 0
Study 8963482 — intervention group
Group type: EXPERIMENTAL
Intervention: Convulsofin (test) tablets (2 tablets each containing 300 mg calcium valproate, 263.4 mg valproic acid)
Number of subjects: 16
Study 8963482 — intervention group
Group type: EXPERIMENTAL
Intervention: Convulsofin (test) tablets
Number of subjects: 16
Study 8963482 — intervention group
Group type: COMPARATOR
Intervention: ref.A (2 dragees each of 300 mg calcium valproate)
Number of subjects: 16
Study 8963482 — intervention group
Group type: COMPARATOR
Intervention: ref.B (600 mg sodium valproate in liquid form)
Number of subjects: 16
Study 1785001 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical chemo- and immunotherapy
Number of subjects: 60
Study 1785001 — intervention group
Group type: COMPARATOR
Intervention: Transurethral resection (TUR)
Number of subjects: 60
Study 1785001 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical cytostatics
Number of subjects: 60
Study 1785001 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical bacillus Calmette-Guérin
Number of subjects: 60
Study 1785001 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant prophylactic treatments
Number of subjects: 60
Study 1785001 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment of T1G3 cancer
Number of subjects: 60
Study 7023516 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxprenolol
Number of subjects: 20
Study 7023516 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 20
Study 31362531 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-duration HIIT (SDHIIT, n = 10)
Number of subjects: 30
Study 31362531 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-duration HIIT (LDHIIT, n = 10)
Number of subjects: 30
Study 31362531 — intervention group
Group type: COMPARATOR
Intervention: Control (n = 10)
Number of subjects: 30
Study 30830724 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertugliflozin 5 mg
Number of subjects: 506
Study 30830724 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertugliflozin 15 mg
Number of subjects: 506
Study 30830724 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 506
Study 27783367 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 71
Study 27783367 — intervention group
Group type: COMPARATOR
Intervention: Intensive medical management (IMM)
Number of subjects: 71
Study 26469986 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid combination antiretroviral therapy (ART) initiated by pregnant women
Number of subjects: 16
Study 26469986 — intervention group
Group type: EXPERIMENTAL
Intervention: ART or replacement feeding initiated by breastfeeding women
Number of subjects: 16
Study 23379809 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee-length shorts (SHORTS)
Number of subjects: 15
Study 23379809 — intervention group
Group type: COMPARATOR
Intervention: Full-length pants (PANTS)
Number of subjects: 15
Study 21864886 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined modality integrative medicine (CM‐IM) including hypnosis, therapeutic massage, and healing touch with each cycle of chemotherapy
Number of subjects: 43
Study 21864886 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined modality integrative medicine (CM‐IM)
Number of subjects: 43
Study 21864886 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy without CM‐IM
Number of subjects: 43
Study 19645779 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulvestrant (first line: 2%, second line: 40%, third line: 29%, fourth line: 22%, fifth line: 7%)
Number of subjects: 45
Study 19645779 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Number of subjects: 45
Study 19645779 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulvestrant (in patients with clinical benefit)
Number of subjects: 45
Study 17915642 — intervention group
Group type: EXPERIMENTAL
Intervention: Test drug (loxoprofen 60 mg tablets)
Number of subjects: 0
Study 17915642 — intervention group
Group type: COMPARATOR
Intervention: Reference drug (loxoprofen 60 mg tablets)
Number of subjects: 0
Study 15548972 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (3 mg/day) + Reduced-Dose Neoral (RDN)
Number of subjects: 111
Study 15548972 — intervention group
Group type: COMPARATOR
Intervention: Everolimus (3 mg/day) + Full-Dose Neoral (FDN)
Number of subjects: 111
Study 11672943 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam 0.16 mg (slow onset)
Number of subjects: 36
Study 11672943 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam 0.8 mg (fast onset)
Number of subjects: 36
Study 11672943 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam 0.25 mg (slow onset)
Number of subjects: 36
Study 11672943 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam 1.25 mg (fast onset)
Number of subjects: 36
Study 11672943 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam 0.4 mg (slow onset)
Number of subjects: 36
Study 11672943 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam 2 mg (fast onset)
Number of subjects: 36
Study 11672943 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 9141914 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopexamine 0.5 micrograms.kg‐1.min‐1
Number of subjects: 44
Study 9141914 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopexamine 1.0 micrograms.kg‐1.min‐1
Number of subjects: 44
Study 9141914 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopexamine 2.0 micrograms.kg‐1.min‐1
Number of subjects: 44
Study 9141914 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopexamine (all doses)
Number of subjects: 44
Study 9141914 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 7944696 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-coated bypass circuits with an uncoated cardiotomy reservoir
Number of subjects: 20
Study 7944696 — intervention group
Group type: COMPARATOR
Intervention: Standard uncoated bypass circuits
Number of subjects: 20
Study 7944696 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-coated bypass circuits
Number of subjects: 20
Study 7944696 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study 3060281 — intervention group
Group type: EXPERIMENTAL
Intervention: Postocclusive reactive circulatory hyperaemia (PORCH) test
Number of subjects: 144
Study 3060281 — intervention group
Group type: COMPARATOR
Intervention: Allen's test
Number of subjects: 144
Study 30479531 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent Training (CT) - high-intensity intermittent training plus strength training, performed twice weekly for 12 weeks.
Number of subjects: 19
Study 30479531 — intervention group
Group type: COMPARATOR
Intervention: Strength Training (ST) - strength training sessions only, performed twice weekly for 12 weeks.
Number of subjects: 19
Study 28578652 — intervention group
Group type: EXPERIMENTAL
Intervention: CROSS protocol (Carboplatin and Paclitaxel with concurrent radiotherapy, 41.4Gy/23Fr, over 5 weeks)
Number of subjects: 594
Study 28578652 — intervention group
Group type: EXPERIMENTAL
Intervention: CROSS protocol
Number of subjects: 594
Study 28578652 — intervention group
Group type: COMPARATOR
Intervention: Standard perioperative chemotherapy regimen (not explicitly detailed in the abstract)
Number of subjects: 594
Study 26313454 — intervention group
Group type: EXPERIMENTAL
Intervention: NAP/ESO (naproxen 500 mg/esomeprazole 20 mg, twice daily)
Number of subjects: 1219